此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Inter- and Intra-Rater Reliability of a Wearable Inertial Sensor for Spatiotemporal Gait Assessment in Stroke Survivors

2026年6月10日 更新者:Alejandro Herrera Rojas、Neuron, Spain

Background and Objective:

Stroke frequently impairs gait functionality, leading to significant limitations in functional independence and quality of life. Objective gait analysis is essential for evaluating clinical status and rehabilitation progress. While laboratory-bound, non-wearable systems are considered the gold standard, their high cost, complex infrastructure, and requirement for specialized personnel limit their routine implementation in daily clinical practice. Portable inertial measurement units have emerged as a practical, low-cost alternative for motion analysis outside traditional laboratory settings. However, evidence regarding specific commercial devices in pathological populations remains limited. This study aims to evaluate the inter-rater and intra-rater reliability of the commercially available Baiobit® lumbar-mounted inertial sensor for measuring spatiotemporal gait parameters in stroke survivors.

Methodology:

A prospective, single-group, repeated-measures design was conducted at a specialized neurorehabilitation clinic (Neuron Clinic, Madrid). A convenience sample of 22 adults diagnosed with subacute or chronic stroke who were able to ambulate independently was included. Gait assessments were performed by two trained evaluators across two separate sessions spaced 24 to 48 hours apart. During each session, the Baiobit® sensor was secured to the participants' sacral region (S1-S2) using an adjustable belt. Participants performed three 10-meter walking trials at their comfortable, self-selected pace for each evaluator. Reliability was quantified using Intraclass Correlation Coefficients (ICC), Standard Error of Measurement (SEM), and Minimal Detectable Change (MDC).

Expected Outcomes:

It is hypothesized that the Baiobit® inertial sensor will demonstrate adequate relative and absolute inter- and intra-rater reliability across spatiotemporal gait parameters, supporting its viability as an objective monitoring tool in routine stroke rehabilitation clinical settings.

研究概览

地位

完全的

条件

详细说明

Introduction and Rationale Stroke survivors commonly experience sensorimotor sequelae that heavily compromise walking patterns, typically presenting reduced speed, lower cadence, shortened step length, and prolonged double-support time. Objective quantification of these spatiotemporal parameters is critical to direct therapeutic goals and evaluate rehabilitation outcomes. To overcome the financial and logistical barriers of traditional motion laboratories, wearable inertial measurement units (IMUs) are increasingly proposed due to their portability and ease of use. However, substantial heterogeneity in sensor configurations and algorithms necessitates population-specific metric validation. The Baiobit® system is an emerging commercial IMU that integrates a triaxial accelerometer, gyroscope, and magnetometer operating at 200 Hz to estimate gait metrics via internal event-detection algorithms. To date, no study has established its measurement consistency and repeatability specifically for stroke survivors.

Study Population and Eligibility Participants were recruited via convenience sampling from the outpatient database at Neuron Clinics in Madrid, Spain. To ensure safety and protocol compliance, strict eligibility criteria were applied: Inclusion Criteria: (1) Adults aged 18 to 85 years; (2) a confirmed diagnosis of ischemic or hemorrhagic stroke with a time since onset $> 1$ month; (3) ability to ambulate independently (Functional Ambulation Categories FAC > 4) regardless of foot-up orthosis use; (4) capacity to walk 10 meters without stopping and repeat the trial six times across the protocol; and (5) cognitive ability to understand instructions and provide written informed consent. Exclusion Criteria: (1) Medical instability or acute conditions comprising gait safety; (2) concomitant neurological conditions other than stroke; (3) severe musculoskeletal disorders interfering with locomotion; (4) visual or auditory deficits severely impairing balance; (5) recent use of medications affecting gait or postural control (e.g., benzodiazepines, antipsychotics, or opioids); and (6) pregnancy. Randomization and Blinding Protocols To control for sequence and order biases, a 1:1 block randomization scheme was generated using a digital tool (randomizer.org) to determine the evaluation sequence between the two raters. Blinding was coordinated by a third independent researcher who managed the logistical workflows, handled independent password-protected software accounts for each rater, and exported raw data to a masked master database. This design strictly prevented the two evaluators from assessing participants simultaneously or accessing each other's data records.

Experimental Procedures The data collection protocol spanned two distinct evaluation sessions scheduled 24 to 48 hours apart to minimize clinical fluctuations while preventing recall bias. Familiarization: In the first session, after formal enrollment and collection of sociodemographic data, participants were familiarized with the environment, and the 10-meter walkway was demonstrated. Sensor Placement: The Baiobit® sensor was securely mounted on the sacral region corresponding to the S1-S2 vertebrae using the manufacturer's adjustable elastic belt. Data Acquisition: Participants performed three 10-meter walking trials at their comfortable, self-selected pace per evaluator. The first assigned evaluator positioned the sensor, acquired the recordings, and completely removed the device. Rest Period: A mandatory 10-minute seated rest period was enforced between evaluators to mitigate fatigue effects. Replication: The second evaluator repeated the exact preparation, placement, and trial recording steps. This identical sequence was replicated during the second session under unvaried environmental conditions.

Outcome Measures and Biomechanical Variables Spatiotemporal gait variables were recorded bilaterally by the sensor software algorithms, capturing: gait speed (m/s), cadence (steps/min), step and stride lengths (m), percentages (%) of stance and swing phases, single-leg and double-leg stance durations, and propulsion metrics. Statistical Analysis PlanData normality was verified using the Shapiro-Wilk test. Continuous demographics are reported as mean and standard deviation (SD). Relative reliability was analyzed using Intraclass Correlation Coefficients (ICCs) with 95% confidence intervals (95% CIs). A two-way mixed-effects consistency model was selected for intra-rater reliability, and a two-way random-effects absolute agreement model was utilized for inter-rater reliability. Absolute reliability and precision were quantified calculating the Standard Error of Measurement. The Minimal Detectable Change was calculated to define the true clinical change threshold. Bland-Altman plotting was performed to identify systematic biases and calculate the limits of agreement (LoA).

研究类型

观察性的

注册 (实际的)

24

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Madrid
      • Madrid、Madrid、西班牙、28045
        • Neuron Madrid Río

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

The study population consists of a convenience sample of adult stroke survivors receiving outpatient physical therapy and neurorehabilitation care. Participants include individuals with a confirmed diagnosis of either ischemic or hemorrhagic stroke, in both subacute and chronic stages (time since onset greater than one month), who retain the functional capacity to ambulate independently on overground surfaces without physical assistance. All participants are recruited from the outpatient facilities of a specialized neurorehabilitation center (Neuron Clinics) located in Madrid, Spain.

描述

Inclusion Criteria:

  • adults aged 18-85 years
  • confirmed diagnosis of stroke
  • ability to ambulate (FAC > 4), regardless of foot-up use
  • Capacity to walk 10m without stopping and repeat the trials 6 times across the session
  • Cognitive ability to understand the study instruction and provide written informed consent

Exclusion Criteria:

  • clinical instability or acute medical conditions that compromise gait safety
  • concomitant neurological conditions other than stroke
  • severe musculoskeletal disorders that interfere with gait analysis
  • balance or coordination impairments secondary to visual or auditory deficits
  • recent use of substances or medications that impair bait, balance, or postural control
  • pregnancy
  • cognitive or behavioral impairments that prevent the proper performance of the test

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Participants
All the participants included

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Intra-rater reliability of spatiotemporal gait parameters
大体时间:Up to 48 hours
Relative and absolute consistency of spatiotemporal gait metrics derived from repeated measurements taken by the same evaluator
Up to 48 hours

次要结果测量

结果测量
措施说明
大体时间
Inter-rater reliability of spatiotemporal gait parameters
大体时间:Day 1 and day 2
Relative and absolute consistency of spatiotemporal gait metrics recorder simultaneously by two independent, trained evaluators
Day 1 and day 2

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Alejandro Herrera Rojas, Physical Therapist、Neuron, Spain

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年10月10日

初级完成 (实际的)

2026年4月20日

研究完成 (实际的)

2026年5月14日

研究注册日期

首次提交

2026年6月10日

首先提交符合 QC 标准的

2026年6月10日

首次发布 (实际的)

2026年6月16日

研究记录更新

最后更新发布 (实际的)

2026年6月16日

上次提交的符合 QC 标准的更新

2026年6月10日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • Baiobit validation in stroke

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Database used for the analyses will be published in zenodo website

IPD 共享时间框架

Data will be uploaded once analyzed

IPD 共享访问标准

Anybody

IPD 共享支持信息类型

  • 分析代码

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅